Subsequently, compound S107, an orally available 1,4-benzothiazepine derivative with high potency on RyR2 and no significant off-target effects, was shown to suppress ventricular arrhythmias in a RyR2 R2474S knock-in mouse model (Lehnart et al., 2008). Here, RYR2 is linked to Ventricular arrhythmia.